Hims & Hers (HIMS) Stock Forecast: Price Prediction 2025–2030

Last Updated: July 14, 2025

HIMS Stock Quick Summary

Current Price: $23.14 (as of July 14, 2025, Source: Yahoo Finance) 52-Week High: $72.94 (January 2025) 52-Week Low: $12.10 (April 2025) Market Cap: $5.1B (as of July 14, 2025) Analyst Consensus: Moderate Buy (Source: MarketBeat, July 14, 2025) Avg. 12-Month Price Target: $34.20 (Source: MarketBeat, July 14, 2025) HIMS Stock Outlook: Cautiously Bullish. Meaningful analyst upside implied, contingent on FDA compounding litigation resolution.

As of July 14, 2025, Wall Street analysts covering Hims & Hers Health, Inc. (NYSE: HIMS) hold a consensus 12-month price target of $34.20, implying approximately 48% upside from the current price of $23.14. Yet the stock sits roughly 68% below its January 2025 peak of approximately $72.94. The decline traces directly to a single regulatory event: the FDA's determination that the semaglutide shortage had been resolved, which removed the legal basis for the compounding pharmacy network that powered HIMS's most explosive growth period.

HIMS climbed from roughly $4 in early 2023 to nearly $73 in January 2025 as compounded semaglutide (the active ingredient in Ozempic and Wegovy) turned into a major revenue driver. Then the FDA's shortage resolution announcement wiped out more than half the market cap in weeks. The question now before every investor holding or considering HIMS shares is whether the fundamental thesis is broken or temporarily impaired.

This HIMS stock analysis covers the HIMS stock forecast from 2025 through 2030, including year-by-year price prediction ranges, the FDA and GLP-1 receptor agonist regulatory story examined in depth, quantitative bull and bear case scenarios, and the analyst consensus data needed to evaluate the investment case. This analysis is for informational purposes only. Stock forecasts involve inherent uncertainty. All estimates should be treated as analytical frameworks, not investment recommendations.

HIMS Stock Price Prediction 2025–2030

The table below summarizes the HIMS 5-year forecast spanning low, base case, and high estimates derived from analyst consensus data and disclosed scenario modeling assumptions. Year-by-year rationale appears in the section following the table; bull and bear scenario assumptions are detailed in the scenario modeling section.

Estimates as of July 14, 2025. All figures are scenario-based projections derived from analyst consensus data and disclosed modeling assumptions. Past performance does not guarantee future results.

For context on how bull and bear scenario ranges are constructed for growth stocks facing regulatory transitions, see AMC Stock Forecast: A Scenario Framework for Price Ranges, Drivers and Risk.

What Is Hims & Hers Health?

Hims & Hers Health, Inc. (NYSE: HIMS) is a telehealth and direct-to-consumer (DTC) wellness company that connects patients with licensed clinicians online and ships prescription and over-the-counter treatments directly to their door, bypassing traditional pharmacy chains and insurance networks. The company operates two consumer brands (Hims for men's health and Hers for women's health) covering hair loss, erectile dysfunction, mental health, skincare, and weight management.

The business model is the product. What patients experience as a subscription delivery of medication is, from an investor's perspective, a recurring-revenue platform that bypasses the entire traditional healthcare distribution chain. The process runs in three steps: a patient completes an online health consultation with an affiliated licensed clinician, the clinician writes a prescription where appropriate, and the treatment ships directly to the patient's door. By eliminating pharmacy markups and insurance middlemen, HIMS generates gross margins approaching 80% on some product lines. The out-of-pocket cash-pay model that enables these margins also constrains the addressable market. Patients who depend on insurance coverage for medication costs are largely excluded from the HIMS model. That tradeoff (high margin, narrower accessible market) is a defining feature of the investment thesis, not a flaw to overlook.

HIMS's product verticals span five categories. The hair loss treatments include finasteride (a prescription DHT-blocking medication used for male pattern baldness) and minoxidil (available in both standard topical formulation and higher-dose oral prescription formulation, the oral version being a HIMS differentiator vs. OTC brands that cannot offer the prescription-strength dose). The sexual health vertical covers ED treatments including sildenafil (generic Viagra) and tadalafil (generic Cialis). Mental health and skincare round out the platform for both brands. The weight loss vertical offered compounded semaglutide and compounded tirzepatide, both subject to the FDA shortage authorization framework described in detail in the Key Catalysts section below.

Hims & Hers was co-founded in 2017 by Andrew Dudum, who remains CEO and a significant insider shareholder. The company went public in January 2021 through a SPAC merger with Oaktree Acquisition Corp. (a blank-check company formed to take private companies public without a traditional IPO process), listing on the NYSE at an implied valuation of approximately $1.6 billion. HIMS reached positive adjusted EBITDA (which excludes stock-based compensation and other non-cash charges; GAAP net income may still be negative) in 2024, a milestone that growth investors had been monitoring as a credibility signal for the business model's underlying economics.

The weight loss vertical connected HIMS to one of the largest pharmaceutical market opportunities of the decade. GLP-1 receptor agonists (a class of weight-loss and diabetes medications including semaglutide and tirzepatide) became a cultural and financial phenomenon between 2023 and 2025. HIMS's entry into this market, and the FDA regulatory event that disrupted it, is the single most important context for understanding where the stock trades today and where it may go through 2030.

For a complete breakdown of the HIMS business model, competitive landscape, and risk factors, see Hims & Hers Stock (NYSE: HIMS): Complete Investor's Guide.

HIMS Stock Price History: From SPAC IPO to Post-Selloff

The HIMS stock chart shows one of the more dramatic arcs in small-cap healthcare: from a SPAC listing near $6 in January 2021, through a multi-year decline to roughly $4 by early 2023, to an explosive peak of approximately $72.94 in January 2025, then a sharp reversal following the FDA's semaglutide shortage resolution announcement. The 52-week high of $72.94 and 52-week low of $12.10 (both within a single calendar year) reflect the regulatory binary the stock now represents.

Source: Yahoo Finance, verified July 14, 2025.

Why Did HIMS Stock Drop?

HIMS stock fell approximately 68% from its January 2025 peak of roughly $72.94 after the FDA declared the semaglutide shortage resolved in March 2025, removing the legal authorization for 503B outsourcing facilities (FDA-regulated compounding operations that can produce drugs in bulk during designated shortages) to produce compounded semaglutide at commercial scale. The decline was not a company-specific operational failure. HIMS did not miss earnings, lose customers through service failures, or face a product recall. The drop reflected a regulatory determination that eliminated a major revenue pathway overnight.

The mechanism matters for understanding the investment case. HIMS was not manufacturing semaglutide. The company operated as a DTC telehealth platform connecting patients to compounded semaglutide produced by third-party 503B outsourcing facilities. When the FDA shortage designation ended, those facilities lost the legal authority to produce the drug at commercial scale, and HIMS lost access to the product. HIMS and the broader compounding pharmacy industry pursued legal challenges to the FDA's shortage resolution determination, arguing the shortage had not in fact been resolved. As of July 14, 2025, those legal proceedings remain active in federal court.

The full regulatory mechanism and its implications for the 2025–2030 forecast are covered in depth in the Key Catalysts section below.

Hims & Hers Business Fundamentals

Hims & Hers reported $1.48 billion in revenue for fiscal year 2024 (Source: HIMS FY2024 earnings release, February 2025), representing approximately 67% year-over-year growth, a trajectory that powered the stock's ascent and now frames the valuation question investors face as GLP-1 revenue faces structural disruption.

Key Financial Metrics

Sources: HIMS earnings releases via ir.forhims.com; Yahoo Finance; MarketBeat. Data as of July 14, 2025.

The GAAP net loss reflects significant stock-based compensation expense, which is excluded from adjusted EBITDA. Investors evaluating HIMS on a profitability basis should treat adjusted EBITDA as an operational signal, not a complete picture of net economic return to shareholders.

Subscriber Growth and ARPU

A HIMS subscriber is a customer on an active recurring subscription for at least one product. This is distinct from registered users or one-time purchasers. Average revenue per user (ARPU) measures the average annual spend per active subscriber. HIMS also reports monthly online revenue (MOR), its primary top-line reporting metric, which captures all subscription and transaction revenue in a given month.

Source: HIMS quarterly earnings releases, ir.forhims.com. Subscriber = active recurring subscription; ARPU = annual average revenue per subscriber.

Subscriber growth accelerated through 2024 as the weight loss vertical added new subscribers at a pace that outpaced legacy vertical churn. The critical question for the 2025–2027 forecast is whether HIMS can retain the subscriber base as compounded semaglutide becomes unavailable. Subscribers who enrolled specifically for weight loss injections represent a meaningfully different retention profile than legacy hair loss and ED subscribers, who tend to remain on treatment for years. The bull case assumes HIMS retains 65–70% of the GLP-1 subscriber cohort through either legal restoration of compounding or alternative product pathways; the bear case assumes 35–40% attrition from that cohort.

Valuation: How Analysts Price HIMS

Analysts typically value HIMS using a Price-to-Sales (P/S) ratio, calculated by dividing the company's market capitalization by its annual revenue, because GAAP earnings-based metrics are less meaningful for a company still carrying significant stock-based compensation expense. At the current price of $23.14 and trailing-twelve-month revenue of approximately $1.52 billion, HIMS trades at a forward P/S of approximately 3.1x on consensus FY2025 revenue estimates of roughly $1.6 billion (Source: StockAnalysis.com analyst consensus, July 2025). Teladoc Health (NYSE: TDOC), the closest publicly traded peer, trades at approximately 0.9x forward revenue, a substantially lower multiple that reflects Teladoc's declining revenue trajectory and ongoing profitability challenges following its Livongo acquisition. HIMS's premium to TDOC is justified by superior revenue growth rates, but that premium compresses if GLP-1 revenue permanently exits the model.

HIMS Stock Price Prediction 2025

As of July 14, 2025, the HIMS stock price prediction for 2025 ranges from $16 (bear case, adverse FDA litigation outcome) to $45 (bull case, favorable court ruling restoring compounding), with an analyst consensus 12-month average target of $34.20 contingent primarily on the FDA compounding litigation outcome and the stability of the company's core legacy subscriber base. The average target implies approximately 48% upside from the current price of $23.14 (Source: MarketBeat analyst consensus, July 14, 2025).

What Could Drive HIMS Higher in 2025

HIMS stock could appreciate meaningfully in the second half of 2025 if a favorable court ruling temporarily or permanently restores the compounding authorization for semaglutide, or if Q2 and Q3 earnings reports demonstrate that legacy subscriber retention has held above analyst expectations. The analyst consensus 12-month target of $34.20 implies 48% upside from the current level. That implied upside reflects analyst conviction that the legacy business alone justifies a price materially above where the stock currently trades. A second catalyst is ARPU expansion through product cross-sell: subscribers who added weight loss to an existing hair or ED subscription retain higher ARPU even after the weight loss product is no longer available, provided they remain on the platform.

Near-Term Catalyst Calendar (Next 3 Months)

The following events are the primary near-term directional drivers for HIMS stock, presented as a catalyst calendar rather than a price prediction. Short-term price precision is not credible given the binary nature of the FDA litigation outcome.

• Q2 2025 Earnings Release (expected August 2025): Subscriber count, MOR, and ARPU figures will be the leading indicators of post-FDA retention. A subscriber count above 2.0M with stable ARPU would support the bull case; a significant decline would confirm the bear case's attrition assumptions.
• FDA Shortage Status Updates: Any FDA announcement regarding semaglutide or tirzepatide shortage designations (track at FDA Drug Shortage Database) could move the stock sharply in either direction.
• Court Rulings on Compounding Pharmacy Legal Challenges: HIMS and compounding industry associations have pursued legal challenges to the FDA's shortage resolution determination. Any appellate court ruling or preliminary injunction would be a material catalyst.
• Institutional Investor Positioning: 13F filings due in August 2025 will reveal whether institutional holders added or reduced positions following the April 2025 low.
• New Product or Partnership Announcements: Any management announcement of alternative GLP-1 pathways (branded pharmaceutical partnerships, new drug formulations) would directly address the central bear case risk.

HIMS Stock Price Prediction 2026–2030: Year-by-Year Outlook

The HIMS stock price prediction for 2026 through 2030 reflects a business in transition. The near-term question of regulatory survival gives way to longer-term questions about organic growth, ARPU expansion, and the company's ability to build durable revenue without the GLP-1 compounding tailwind.

HIMS Stock Forecast 2026

The 2026 base case of $32 assumes the FDA litigation has reached a definitive resolution and HIMS has absorbed the GLP-1 revenue disruption. By 2026, the company's operating reality under either the bull or bear regulatory outcome becomes the foundation for forward modeling. The base case assumes HIMS retains approximately 1.8–2.0 million subscribers at annual ARPU of $300–$320 (compressed from the 2024 peak as GLP-1 subscribers either churn or migrate to lower-ARPU legacy products), generating approximately $560–$640M in annualized legacy revenue. At a forward P/S of 5x on that revenue base, the base case implies a market cap of roughly $2.8–$3.2B and a per-share price in the $28–$32 range. The 2026 forecast is the first full year in which investors can evaluate HIMS's ability to grow without semaglutide, making it the critical inflection year for whether the legacy business can stand on its own.

HIMS Stock Forecast 2027

The 2027 base case of $40 assumes HIMS has demonstrated two consecutive years of subscriber growth in its legacy verticals, with ARPU beginning to recover through cross-sell of mental health, skincare, and new product additions. By 2027, the question shifts from "will HIMS survive without semaglutide?" to "at what rate can HIMS grow organically?" Subscriber cross-sell is the mechanism: a customer who uses both finasteride for hair loss and sildenafil for ED generates roughly 1.7x the ARPU of a single-vertical subscriber. The bull case for 2027 assigns a $70 target based on 2.5M+ subscribers at $380 annual ARPU equating to approximately $950M revenue, trading at 7.5x forward P/S. Potential new product category launches (HIMS has signaled interest in hormone health, fertility support, and metabolic health areas beyond GLP-1) represent the key upside variable that distinguishes a $40 base case from a $70 bull case.

HIMS Stock Forecast 2028–2029

The 2028–2029 forecast range of $20–$85 reflects a period where bull and bear scenario trajectories diverge most dramatically. In the base case, 2028 brings HIMS to approximately $46 as the subscriber base crosses 3M and ARPU stabilizes around $350 annually. In the bear case, HIMS plateaus near $20 if subscriber attrition from the GLP-1 cohort was larger than assumed and the legacy business fails to fill the gap. By 2029, compounding ARPU effects from a maturing subscriber base push the base case toward $52, while uncertainty compounds significantly at this time horizon. Any estimates for 2028–2029 should be treated as directional scenario analysis, not precise forecasts. International expansion into markets such as Canada or the UK represents a potential upside catalyst for these years that the base case does not model in detail.

HIMS Stock Forecast 2030

As of July 2025, the HIMS stock price forecast for 2030 ranges from $15 (bear case) to $110 (bull case), with a base case estimate of approximately $58, contingent on the company achieving consistent subscriber growth of 15–20% annually from a post-GLP-1 baseline and maintaining ARPU above $340 through product diversification.

Scenario modeling based on HIMS FY2024 earnings data (Source: ir.forhims.com, February 2025) and analyst consensus revenue estimates (Source: StockAnalysis.com, July 2025). Shares outstanding assumed at approximately 220–230M. Five-year stock price predictions carry substantial uncertainty and should be treated as scenario analysis, not precise forecasts.

For context on how multi-year forecast scenarios are constructed for technology-adjacent growth companies, see Tesla Stock Price Prediction for 2040: A Beginner Guide to Scenarios, Not Certainties.

HIMS Stock Bull Case and Bear Case

Can HIMS Stock Recover? The Bull Case

HIMS stock could recover substantially if the FDA litigation resolves favorably, restoring compounding authorization, or if HIMS successfully transitions GLP-1 patients to alternative product pathways while maintaining legacy subscriber momentum. The historical precedent is relevant context: HIMS recovered from a 52-week low near $4 in early 2023 to approximately $72.94 by January 2025, a 17x move in under two years driven by a single business catalyst. The stock has demonstrated the capacity for dramatic recovery when the investment thesis aligns with execution.

Source: Scenario modeling based on FY2024 HIMS subscriber and ARPU data (ir.forhims.com). Math verified independently. Forward multiple based on HIMS's pre-GLP-1 surge P/S range of 5–8x.

At the current forward P/S of approximately 3.1x (below HIMS's 2022–2023 trading range of 4–6x during the pre-GLP-1 period), a case can be made that the stock already prices in significant permanent GLP-1 revenue loss. If the company can demonstrate stable subscriber retention through the Q2–Q3 2025 earnings cycle, multiple expansion toward 5–6x would alone generate 60–90% upside from current levels without requiring any GLP-1 revenue recovery. Analyst consensus Buy and Moderate Buy ratings from firms including Cantor Fitzgerald (12-month target $36, July 2025), Jefferies (12-month target $38, July 2025), and Piper Sandler (12-month target $30, July 2025) reflect this valuation argument (Source: MarketBeat, July 2025). The bull case requires multiple conditions to align. No single catalyst guarantees the outcome.

HIMS Stock Bear Case: What If Semaglutide Revenue Is Gone Permanently?

The bear case begins with what the FDA's shortage resolution actually means in legal terms. "Permanently ended" in this context means HIMS's legal challenges are unsuccessful, no court injunction restores compounding authorization, and the FDA maintains its shortage resolution determination. This is not a hypothetical scenario; it is the current operating baseline. HIMS is currently unable to offer compounded semaglutide at commercial scale, and the legal pathway to restoration remains uncertain as of July 14, 2025.

Source: Scenario modeling based on FY2024 HIMS earnings data (ir.forhims.com). Bear case ARPU assumes GLP-1 subscriber attrition skews toward higher-ARPU customers.

GLP-1 and weight loss products contributed an estimated 35–40% of FY2024 revenue growth (based on HIMS Q4 2024 earnings disclosure, February 2025, in which management noted the weight loss vertical as the primary driver of incremental subscriber additions). If that cohort churns at 40%, HIMS loses not just the revenue but the ARPU uplift those subscribers contributed to the blended platform average. CEO Andrew Dudum stated in the February 2025 earnings call that the company had "multiple pathways" to address the GLP-1 transition, including exploring branded pharmaceutical partnerships and new compoundable drug formulations. Whether those pathways materialize at sufficient scale to offset GLP-1 revenue loss remains unverified as of July 2025. At the bear case implied price of $12–$15, the current stock at $23.14 is not yet at the floor, suggesting the market has not fully priced in the worst-case scenario, though April's $12.10 low approached that range. These scenarios are analytical frameworks based on disclosed assumptions. Actual outcomes will depend on factors that cannot be fully anticipated.

Both scenarios are plausible. The weight of probability depends on how the FDA litigation resolves over the next 12–24 months.

Key Catalysts and Risks: The FDA and GLP-1 Regulatory Story

Risk Notice: HIMS stock carries above-average regulatory risk. The FDA litigation over compounded semaglutide represents the single most material unresolved variable in any HIMS forecast. Investors should review this section carefully before making any investment decision.

The FDA's regulatory action on compounded semaglutide is not a minor headwind for Hims & Hers. It is the proximate cause of the stock's 2025 collapse and the single most important variable in every forecast for the next five years.

The FDA Regulatory Timeline: Three Distinct Actions

To understand the HIMS situation accurately, three FDA actions must be kept separate. They are frequently conflated in market commentary, and conflating them produces an incorrect understanding of both the cause of the selloff and the path to recovery.

Compounding pharmacies are facilities that produce customized versions of drugs, typically for patients with specific medical needs not met by commercially available formulations. A 503B outsourcing facility is a specific, FDA-regulated category of larger-scale compounding operation that can produce drugs in commercial volumes during periods of officially designated drug shortages. HIMS did not manufacture semaglutide itself. The company operated as the DTC telehealth platform connecting patients to compounded semaglutide produced by third-party 503B facilities. HIMS is not a compounding pharmacy. This distinction matters for understanding what HIMS can and cannot control in the regulatory outcome.

Action 1: FDA Drug Approval (2017/2021). The FDA approved semaglutide as Ozempic for diabetes management in 2017 and as Wegovy for chronic weight management in 2021. Both are branded products of Danish pharmaceutical company Novo Nordisk (NYSE: NVO). This approval is permanent and unrelated to shortage status. Novo Nordisk has publicly opposed compounding pharmacy production of semaglutide, arguing that the shortage designation was no longer warranted (Source: Novo Nordisk public statements, 2024). This approval action has no bearing on HIMS's current legal situation.

Action 2: FDA Shortage Designation (2022–2024). When the FDA added semaglutide to its official drug shortage list due to supply constraints on branded Ozempic and Wegovy, federal law authorized 503B outsourcing facilities to produce compounded versions of the drug at commercial scale, even without patient-specific prescriptions. This authorization is the legal mechanism that enabled HIMS to offer compounded semaglutide weight loss injections at prices substantially below branded alternatives. HIMS built its GLP-1 business on this shortage authorization. In addition to compounded semaglutide, HIMS also offered compounded tirzepatide (the active ingredient in Eli Lilly's Mounjaro for diabetes and Zepbound for weight loss), which carried its own separate FDA shortage designation and related legal timeline. Verify the current FDA shortage status of tirzepatide separately from semaglutide at the FDA Drug Shortage Database.

Action 3: FDA Shortage Resolution (March 2025). The FDA declared the semaglutide shortage resolved in March 2025 (Source: FDA.gov drug shortage database). Under federal compounding law, this declaration immediately terminated the authorization for 503B facilities to produce compounded semaglutide at commercial scale. Once a drug is removed from the shortage list, continued commercial-scale compounding becomes a legal violation. HIMS lost access to its compounded semaglutide product not because of a direct regulatory action against HIMS specifically, but because the enabling condition (the shortage designation) was removed.

HIMS and the broader compounding pharmacy industry pursued legal challenges to the FDA's shortage resolution determination, arguing that the shortage had not genuinely been resolved and that continued access to compounded semaglutide served a legitimate patient need. As of July 14, 2025, those legal proceedings remain active in federal court (Source: federal court records, July 2025). A favorable ruling for HIMS could restore compounding authorization temporarily or permanently; an adverse ruling would confirm the permanent loss of the product line. Even a favorable court ruling may represent only a temporary reprieve if the FDA resubmits and wins on a subsequent shortage resolution determination.

Can HIMS Sustain Growth Without Semaglutide Revenue?

HIMS can sustain some level of growth without semaglutide revenue, but the trajectory narrows considerably. GLP-1 and weight loss products drove an estimated 35–40% of FY2024's incremental revenue growth (Source: HIMS Q4 2024 earnings, February 2025). The pre-GLP-1 business was itself a growth story: FY2022 revenue was approximately $527M, growing to $787M in FY2023 before the GLP-1 acceleration pushed FY2024 to $1.48B. The legacy business was already demonstrating sustainable growth before the weight loss vertical launched.

HIMS's legacy revenue profile breaks down across four defensible verticals:

• Hair loss vertical (finasteride and minoxidil): High-margin, recurring subscriptions with multi-year retention typical of prescription hair loss treatment. Estimated to represent 30–35% of pre-GLP-1 subscriber base. Finasteride and minoxidil are generic drugs with stable supply chains and no regulatory risk comparable to GLP-1.
• ED vertical (sildenafil and tadalafil): High-margin, defensible subscriptions with the same generic supply chain stability. Estimated 25–30% of pre-GLP-1 subscriber base. HIMS's DTC prescription model creates a meaningful convenience advantage over retail pharmacy alternatives.
• Mental health and skincare verticals: Growing contribution; combined estimated 15–20% of pre-GLP-1 subscribers, with higher growth potential as HIMS expands its mental health formulary.
• Total estimated legacy annual revenue base: Approximately $780–$850M based on pre-GLP-1 subscriber levels and ARPU (derived from FY2023 reported metrics, ir.forhims.com).

A simplified quantitative scenario: if HIMS retains 1.8 million legacy subscribers at annual ARPU of $330 (the approximate pre-GLP-1 blended figure), the company generates approximately $594M in annualized legacy revenue. At a forward P/S of 5x on that revenue, the implied market cap is approximately $2.97B, equating to roughly $13.50 per share on a 220M share count. This floor scenario assumes zero GLP-1 recovery and modest legacy subscriber attrition. It is not the bear case, which assumes heavier attrition. New growth vectors for HIMS beyond GLP-1 include potential branded pharmaceutical distribution partnerships, oral hormone health products, fertility support services, and cautious international expansion. None of these are yet material enough to model with confidence, but they represent the optionality embedded in the bull case premium.

Key Catalysts to Watch

• FDA litigation outcome: The highest-impact single event for HIMS stock through 2026. A court ruling is expected within 2025–2026 based on typical federal case timelines, though litigation schedules are unpredictable.
• Quarterly earnings (subscriber count and ARPU): Q2 and Q3 2025 reports will be the first post-FDA data on legacy subscriber retention. These figures are the leading indicators of which scenario trajectory is unfolding.
• FDA shortage database updates for semaglutide and tirzepatide: Monitor the FDA Drug Shortage Database for any re-designation or status change.
• Court injunctions: A preliminary injunction granted in favor of the compounding industry would temporarily restore HIMS's product access and likely trigger a sharp stock recovery.
• New product launches and therapeutic category announcements: Any management confirmation of alternative GLP-1 pathways or new product verticals would directly address the central bear case concern.
• Analyst rating changes: Upgrades from Hold to Buy or downgrades from Buy to Hold carry disproportionate sentiment impact for a stock with elevated short interest.
• Broader telehealth regulatory environment: Any Congressional or FDA action affecting telehealth prescribing rules for controlled or Schedule-adjacent substances could affect HIMS's clinical model.

As of July 2025, HIMS short interest stands at approximately 14% of the float (Source: MarketBeat, July 2025). Elevated short interest reflects bearish institutional conviction about the FDA litigation outcome, but it also creates the potential for a short squeeze if positive catalysts emerge, particularly a favorable court ruling that would likely trigger forced short covering.

Wall Street Analyst Ratings and Price Targets for HIMS

As of July 14, 2025, the average Wall Street analyst price target for HIMS stock is $34.20, representing approximately 48% upside from the current price of $23.14, based on coverage from 14 analysts. The 12-month target range spans from a low of $18 to a high of $52. The majority of analysts covering HIMS rate it a Moderate Buy, with 9 Buy ratings, 4 Hold ratings, and 1 Sell rating (Source: MarketBeat, July 14, 2025).

For a deeper breakdown of what analysts project for HIMS across multiple time horizons, see HIMS Stock Prediction: What Analysts Project for Hims & Hers in 2025 and Beyond.

HIMS Analyst Ratings and Price Targets

Sources: MarketBeat as of July 14, 2025. Analyst targets are 12-month forward-looking forecasts from their issuance dates; they are not year-specific multi-year price predictions and should not be interpreted as such.

These 12-month targets differ from the 2025–2030 forecast table above. Each analyst target represents an individual firm's view of where HIMS should trade within 12 months of the target's issuance date, based on that firm's proprietary financial model, not the multi-year scenario analysis in the forecast table.

The spread between the low analyst target ($18) and the high ($52) is notably wide by sector standards, roughly 3x from floor to ceiling. That spread directly reflects the binary nature of the FDA litigation outcome. Analysts with Buy ratings are pricing in a favorable court outcome or sufficient legacy business resilience; the Neutral and Sell minority are weighting the bear case more heavily. When the litigation resolves, this spread will compress significantly as analysts converge on a post-resolution thesis.

Analysts typically derive HIMS price targets using a forward P/S multiple applied to consensus revenue estimates. At the current forward P/S of approximately 3.1x on FY2025 revenue estimates of roughly $1.6B, HIMS trades below its 2022–2023 multiple of 4–6x. If the company can restore investor confidence in a sustainable $1.3–$1.5B revenue trajectory without GLP-1, multiple expansion toward the historical range alone implies meaningful appreciation from current levels.

Competitive Landscape: How HIMS Compares to Its Peers

Hims & Hers competes across two distinct fronts: in the telehealth and DTC health delivery space against Teladoc Health (NYSE: TDOC) and private platforms including Ro Health, and in the weight management category against the branded GLP-1 products of Novo Nordisk and Eli Lilly.

Teladoc Health (TDOC) is HIMS's most comparable publicly traded peer, though the two companies serve distinct market segments. Teladoc operates a broader general telehealth platform serving employers, health plans, and health systems, a business-to-business-to-consumer model that contrasts with HIMS's direct-to-consumer subscription approach. Teladoc's financial challenges following its 2020 acquisition of Livongo for approximately $18.5 billion (a price that proved to reflect COVID-era telehealth premiums rather than durable enterprise value) left the company with substantial goodwill impairment and ongoing profitability pressure. Teladoc's stock has declined approximately 85% from its 2021 peak. As of July 2025, HIMS trades at approximately 3.1x forward P/S versus Teladoc at approximately 0.9x. HIMS's premium reflects superior revenue growth even after the GLP-1 disruption. HIMS's narrower but deeper focus on specific recurring-treatment categories creates a more defensible subscriber base than Teladoc's broader platform model. The fact that HIMS has outperformed Teladoc on revenue growth metrics even through the GLP-1 headwind is a meaningful data point for the bull case.

HIMS also competes with private DTC platforms including Ro Health (Roman/Rory), which offers similar telehealth prescriptions for ED, hair loss, and weight management without the public market pressure HIMS faces. Ro's continued private funding confirms the competitive intensity of the DTC health category and is relevant to the bear case argument around market saturation risk.

HIMS's competitive moat rests on four reinforcing factors. First, subscription lock-in: patients who have established a treatment relationship with an HIMS-affiliated clinician face behavioral friction when moving to a competitor. Second, brand recognition in sensitive health categories where consumers favor trusted names. Third, proprietary patient outcome data from years of prescription-and-monitor cycles that improve product recommendations. Fourth, DTC price advantage relative to retail pharmacy alternatives for the same generic medications. These moat characteristics existed before GLP-1 and persist after the regulatory disruption. They explain why the legacy business generates 80%+ gross margins and high subscriber retention in hair and ED verticals.

Is Hims & Hers Stock a Good Buy in 2025?

Hims & Hers stock may suit growth investors with a high tolerance for regulatory uncertainty and a 2–3 year investment horizon, given analyst consensus upside of approximately 48% from the current price of $23.14 and an average 12-month target of $34.20. The primary risk is the ongoing FDA compounding litigation. Investors who require certainty on that outcome before committing capital face a waiting period of unknown duration. The 50–70% decline from the January 2025 peak has created meaningful uncertainty for investors who bought at higher prices. The relevant question is whether the fundamental thesis has changed permanently or temporarily.

HIMS May Be Worth Considering If:

• You accept a 2–3 year time horizon and can tolerate drawdowns of 30–40% from your entry point
• You believe the FDA litigation resolves favorably, or that HIMS can demonstrate sufficient legacy subscriber retention to justify a higher forward P/S multiple
• You view the current forward P/S of approximately 3.1x as a discounted entry relative to the historical 4–6x range, given that the legacy business alone generated $787M in FY2023 revenue before GLP-1 acceleration
• Your portfolio can accommodate a position in a high-volatility, growth-stage healthcare company with an active regulatory binary

HIMS May NOT Be Right For You If:

• You require dividend income (HIMS does not pay a dividend and is not expected to initiate one within the 2025–2030 forecast window, given the capital reinvestment priorities of the growth model)
• You cannot absorb continued share price volatility pending a court ruling that could arrive on any business day
• Your investment thesis requires GAAP profitability (HIMS generated positive adjusted EBITDA of $126M in FY2024 but reported a GAAP net loss of approximately $230M due to stock-based compensation expense)
• You are deploying capital you may need access to within 12–18 months, given the binary litigation timeline

As of July 2025, 9 of 14 Wall Street analysts covering HIMS rate it a Buy or equivalent, with the consensus 12-month price target of $34.20 representing 48% upside. That consensus does not guarantee the outcome, and analysts have been wrong on HIMS before (the stock fell well below consensus targets in the weeks following the FDA announcement). The analyst consensus provides a third-party data point on valuation, not a forecast of actual returns.

This analysis is for informational purposes only and does not constitute investment advice. Whether HIMS stock suits your portfolio depends on your individual financial situation, risk tolerance, and investment goals. Consult a qualified financial advisor before making any investment decision.

Frequently Asked Questions About HIMS Stock

What is the HIMS stock price prediction for 2025?

The HIMS stock price prediction for 2025 ranges from $16 (bear case) to $45 (bull case), with an analyst consensus 12-month average target of $34.20 (Source: MarketBeat, July 14, 2025). The forecast assumes stability in the company's legacy subscriber base following the FDA's semaglutide shortage resolution and depends materially on the outcome of ongoing compounding pharmacy litigation. See the full year-by-year forecast table above for detailed low, base, and high estimates through 2030.

Is Hims & Hers stock a good buy?

Hims & Hers stock may be suitable for growth investors with a 2–3 year investment horizon and high tolerance for regulatory risk. The analyst consensus as of July 14, 2025 rates HIMS a Moderate Buy with an average 12-month target of $34.20, implying approximately 48% upside from the current price of $23.14 (Source: MarketBeat). The primary risk is the unresolved FDA compounding litigation. Investors should always conduct their own research and consult a financial advisor before investing.

Why did HIMS stock drop?

HIMS stock dropped approximately 68% from its January 2025 peak of roughly $72.94 after the FDA declared the semaglutide shortage resolved in March 2025, removing the legal authorization for 503B outsourcing facilities to produce compounded semaglutide at commercial scale (Source: FDA.gov drug shortage database, March 2025). The decline reflected the loss of a major revenue pathway, not an operational failure by the company. HIMS and the compounding pharmacy industry have since pursued legal challenges to the FDA's shortage resolution determination, and that litigation remains active as of July 14, 2025.

What is HIMS stock price target?

The average Wall Street analyst 12-month price target for HIMS stock stands at $34.20 as of July 14, 2025, based on coverage from 14 analysts (Source: MarketBeat). The target range spans from a low of $18 to a high of $52, with a Moderate Buy consensus rating. These are 12-month forward-looking targets from their issuance dates, not multi-year price predictions.

Will HIMS stock recover?

HIMS stock could recover meaningfully if the ongoing FDA compounding litigation resolves favorably, restoring some form of semaglutide compounding authorization, or if Q2–Q3 2025 earnings demonstrate that legacy subscriber retention has held above analyst expectations. For historical context, HIMS recovered from a 52-week low near $4 in early 2023 to approximately $72.94 by January 2025, demonstrating a historical capacity for sharp recovery when business catalysts align. Recovery is contingent, not guaranteed, and depends on regulatory, legal, and business execution factors that remain unresolved.

How has HIMS stock performed historically?

HIMS stock went public via SPAC merger with Oaktree Acquisition Corp. in January 2021 at approximately $6 per share, then declined through 2021–2022 as post-SPAC sentiment weighed on growth equities broadly, bottoming near $4 in early 2023. The stock surged to approximately $72.94 in January 2025, driven by explosive growth in the compounded semaglutide weight loss business. Following the FDA's semaglutide shortage resolution in March 2025, the stock fell to a 52-week low of $12.10 in April 2025 before partially recovering to $23.14 as of July 14, 2025 (Source: Yahoo Finance).

What does Hims & Hers actually do?

Hims & Hers Health, Inc. (NYSE: HIMS) is a telehealth and direct-to-consumer (DTC) wellness company that connects patients with licensed clinicians online and ships prescription and OTC treatments directly to their door, bypassing traditional pharmacy chains and insurance networks. The company operates two consumer brands (Hims for men's health and Hers for women's health) offering treatments for hair loss, erectile dysfunction, mental health, skincare, and weight management. Revenue is generated primarily through recurring monthly subscriptions, with transaction revenue from one-time purchases representing a smaller share of total revenue.

What is the HIMS stock forecast for 2030?

The HIMS stock price forecast for 2030 ranges from $15 (bear case: subscriber attrition exceeds new growth, revenue plateau, multiple compression) to $110 (bull case: 5M+ subscribers, international expansion, new therapeutic categories, ARPU above $420), with a base case estimate of approximately $58, contingent on 3.2M subscribers at $360 annual ARPU without semaglutide revenue (Source: Scenario modeling based on ir.forhims.com FY2024 data and StockAnalysis.com consensus, July 2025). Five-year stock price predictions carry substantial uncertainty and should be treated as scenario analysis rather than precise forecasts.

Does HIMS pay a dividend?

No. Hims & Hers Health does not pay a dividend and is not expected to initiate one within the 2025–2030 forecast window. The company reinvests available capital into subscriber acquisition, product development, and platform expansion, consistent with its growth-stage business profile. Investors who require dividend income should note this before evaluating HIMS as a portfolio position.

Who are Hims & Hers competitors?

Hims & Hers competes across two dimensions. In the telehealth and DTC health delivery space, primary competitors include Teladoc Health (NYSE: TDOC), Ro Health (private, operating the Roman and Rory brands), and Amazon Pharmacy. In the weight management category, HIMS competed against the branded GLP-1 products of Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound). HIMS's competitive differentiation rests on its subscription model, brand recognition in sensitive health categories, and the DTC convenience of telehealth-enabled prescription delivery.

How can I trade HIMS on Bybit?

Bybit offers HIMS/USDT perpetual contracts, allowing traders to gain exposure to HIMS price movements with flexible leverage and 24/7 trading availability. Unlike traditional stock brokerages that require a U.S. securities account and operate only during NYSE market hours, Bybit's HIMS/USDT perpetual provides round-the-clock access to HIMS price action with both long and short positioning options. This can be particularly relevant for a stock with binary regulatory catalysts that may produce price-moving news outside of traditional market hours.

Financial Disclaimer

This article is for informational purposes only and does not constitute financial, investment, or trading advice. Stock price predictions involve inherent uncertainty, and past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. This publication does not hold a position in HIMS stock at the time of publication. All financial data cited in this article was sourced from publicly available information as of July 14, 2025, and is subject to change. Analyst price targets and consensus ratings represent third-party views and do not constitute endorsements or recommendations by this publication.

Related Reading

• AMC Stock Forecast: A Scenario Framework for Price Ranges, Drivers and Risk
• Tesla Stock Price Prediction for 2040 (TSLA): A Beginner Guide to Scenarios, Not Certainties
• Hims & Hers Stock (NYSE: HIMS): Complete Investor's Guide
• HIMS Stock Prediction: What Analysts Project for Hims & Hers in 2025 and Beyond